For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 277,803 | 546,204 | ||
| General and administrative | 1,815,775 | 1,304,956 | ||
| Total operating expenses | 2,093,578 | 1,851,160 | ||
| Loss from operations | -2,093,578 | -1,851,160 | ||
| Interest expense | 9,648 | 6,161 | ||
| Interest income | 1,388 | 2,168 | ||
| Total other income (expense), net | -8,260 | -3,993 | ||
| Net loss | -2,101,838 | -1,855,153 | ||
| Basic EPS | -0.34 | -0.64 | ||
| Diluted EPS | -0.34 | -0.64 | ||
| Basic Average Shares | 6,241,909 | 2,877,327 | ||
| Diluted Average Shares | 6,241,909 | 2,877,327 | ||
Tharimmune, Inc. (THAR)
Tharimmune, Inc. (THAR)